US Pharm. 2011;36(4):42.
Watson Pharmaceuticals, Inc., announced that the U.S. District Court for the District of Delaware has ruled that Watson's generic version of Fentora (fentanyl buccal tablets C-II) does not infringe U.S. Patent Nos. 6,200,604 and 6,974,590 (the '604 and '590 patents) and that the '604 and '590 patents are invalid. A decision on U.S. Patent No. 6,264,981 remains outstanding, and Watson cannot launch its generic Fentora. Watson's abbreviated new drug application (ANDA) for its generic version of Fentora has been approved by the FDA.